Analyst Ratings February 4, 2026

Deutsche Bank Reiterates Buy on Eli Lilly After Strong FY26 Guidance and Robust Q4 Results

Bank keeps $1,200 target as Lilly issues upbeat 2026 revenue and EPS outlook; diabetes and obesity drugs drive quarterly outperformance

By Nina Shah LLY
Deutsche Bank Reiterates Buy on Eli Lilly After Strong FY26 Guidance and Robust Q4 Results
LLY

Deutsche Bank maintained a Buy rating and a $1,200.00 price target on Eli Lilly after the company provided fiscal 2026 guidance above consensus and reported fourth-quarter 2025 results that exceeded expectations. Lilly forecast FY26 revenue of $80-$83 billion and non-GAAP EPS of $33.50-$35.00, and reported Q4 revenue and EPS that outpaced Street forecasts, led by strong sales of Mounjaro and Zepbound. Management confirmed key product and coverage timelines, including a planned U.S. launch of Orforg in Q2 2026 and Medicare obesity coverage effective July 1, 2027.

Key Points

  • Deutsche Bank reiterated a Buy rating and maintained a $1,200.00 price target on Eli Lilly following FY26 guidance and Q4 2025 results.
  • Lilly issued FY26 guidance of $80-$83 billion in revenue and non-GAAP EPS of $33.50-$35.00, both above consensus estimates of roughly $78 billion and $33.09 respectively, implying about 42% volume growth given a low-to-mid teens price decline assumption.
  • Q4 2025 results showed roughly $19.3 billion in revenue and $7.54 in EPS, topping expectations, with Mounjaro and Zepbound cited as primary revenue drivers; management also confirmed Orforg U.S. launch timing and Medicare coverage schedule.

Deutsche Bank reaffirmed its Buy rating on Eli Lilly and left its price target at $1,200.00 after the drugmaker released fiscal year 2026 guidance that topped consensus expectations. The guidance calls for FY26 revenue in a range of $80-$83 billion and non-GAAP earnings per share between $33.50 and $35.00, figures that exceed analyst consensus estimates cited at roughly $78 billion in revenue and $33.09 in EPS.

The bank highlighted details embedded in Lilly's guidance about pricing and volume. Management's FY26 outlook assumes a low-to-mid teens price decline, which contrasts with a -6% price decline in FY25. Given that pricing assumption, Lilly's guidance implies approximately 42% year-over-year volume growth for 2026, with Deutsche Bank noting particular upside potential in markets outside the United States.

For the fourth quarter of 2025, Lilly reported revenue of about $19.3 billion, beating Street expectations of $18 billion and exceeding an alternate forecast cited at $17.87 billion. The company posted non-GAAP EPS of $7.54 for the quarter, above the forecast of $7.20. Management attributed the outperformance primarily to strong demand for its diabetes and obesity therapies, Mounjaro and Zepbound.

Management also reiterated product and coverage timelines that bear on future revenue trajectories. Lilly confirmed the U.S. launch of Orforg is on track for the second quarter of 2026. The company also noted that Medicare's obesity coverage is slated to roll out on July 1, 2027, and that Lilly has submitted a European filing for Orforg in Type 2 diabetes.

Deutsche Bank's continued Buy rating follows these forward-looking disclosures and the quarterly beat, which together present a clearer picture of Lilly's expected 2026 performance. The guidance numbers point to a combination of significant volume expansion and geographic growth opportunities, while the quarterly results underline the current strength of Lilly's key product franchises.


Market context and implications

Lilly's FY26 guidance and fourth-quarter metrics directly affect the healthcare and broader equity markets by updating expectations for the company's growth trajectory and profitability. The guidance implies substantial volume-led expansion and highlights the central role of diabetes and obesity treatments in driving near-term revenue.

What management confirmed

  • FY26 revenue guidance: $80-$83 billion
  • FY26 non-GAAP EPS guidance: $33.50-$35.00 per share
  • Q4 2025 revenue: approximately $19.3 billion
  • Q4 2025 EPS: $7.54
  • U.S. Orforg launch: scheduled for Q2 2026
  • Medicare obesity coverage rollout: July 1, 2027
  • Orforg European filing: submitted for Type 2 diabetes

Risks

  • Guidance assumes a low-to-mid teens price decline in FY26; realized pricing dynamics could diverge from this assumption, affecting implied volume growth - this impacts pharmaceutical revenue forecasting and investor expectations in healthcare equities.
  • A significant portion of the quarter's upside was driven by Mounjaro and Zepbound; sustained performance of these products is material to near-term results, creating concentration risk within Lilly's therapeutic portfolio and implications for biotech and healthcare sectors.
  • Key timelines such as the U.S. Orforg launch in Q2 2026 and Medicare obesity coverage rollout on July 1, 2027 are central to revenue projections; any shifts in launch or coverage timing could introduce uncertainty for reimbursement and uptake across payer-driven markets.

More from Analyst Ratings

Coherus Secures Johnson & Johnson Supply Pact for Phase 1b TCE Combination in mCRPC Feb 4, 2026 Leerink Sticks with Outperform on Cencora, Flags Durable Growth Despite Near-Term Revenue Miss Feb 4, 2026 Wolfe Research Keeps Outperform on RTX After Missile Production Framework Deal Feb 4, 2026 Morgan Stanley nudges Evercore price target higher to $381 as earnings outlook improves Feb 4, 2026 Raymond James Lifts Flex Price Target to $80 Citing Data‑center Strength; Nextpower JV Advances Saudi Solar Plans Feb 4, 2026